Epilepsy is the fourth most common neurological disorder in the U.S. It is estimated that about 3 million adults in the country have active epilepsy. Drug therapy is unable to control seizures for 1 in 3 patients. Drug-resistant epilepsy is a devastating, highly undertreated disease with a significant unmet need.
The company we are profiling today is NeuroPace Inc. (NPCE), a medical device company known for its innovative therapy designed for adults suffering from drug-resistant focal epilepsy, marketed under the name RNS System.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.